Quick Answer
Sagimet Biosciences Inc. reported Net Income Loss of -$51.04 million for the year ending 2025.
- Sagimet Biosciences Inc. showed a decrease of -12.0% in Net Income Loss from 2024 to 2025.
- This data is from Sagimet Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$8.74 million | Q2 2022: -$7.10 million | Q3 2022: -$7.47 million | Q1 2023: -$6.59 million | Q2 2023: -$6.79 million | Q3 2023: -$6.35 million | Q1 2024: -$6.63 million | Q2 2024: -$8.12 million | Q3 2024: -$14.62 million | Q1 2025: -$18.18 million | Q2 2025: -$10.39 million | Q3 2025: -$12.91 million.
- Over the full 4 years of available data (2022 to 2025), Sagimet Biosciences Inc.'s Net Income Loss has declined by 67.3%.
- Historical annual values: Fiscal year 2025: -$51.04 million | Fiscal year 2024: -$45.57 million | Fiscal year 2023: -$27.88 million | Fiscal year 2022: -$30.50 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: